Streptokinase is a clot-dissolving medication used in emergencies like heart attacks, pulmonary embolisms, and deep vein thrombosis. It works by activating your body’s own clot-breakdown system, converting an inactive protein in your blood into one that digests clots from the inside. First used in the 1950s, it remains one of the most widely used thrombolytics worldwide, particularly in countries where newer, more expensive alternatives aren’t readily available.
Where Streptokinase Comes From
Streptokinase is not a synthetic drug. It’s a protein produced naturally by certain strains of hemolytic streptococcus bacteria, the same family responsible for strep throat. The strain most commonly used in production is Streptococcus equisimilis, which secretes streptokinase into the surrounding fluid as it grows. To make the medication, manufacturers culture these bacteria, collect the protein they release, and purify it through a series of filtration and chromatography steps to isolate the active molecule from everything else in the bacterial broth.
This bacterial origin is central to both how streptokinase works and why it carries unique risks. Because it’s a foreign protein from a common human pathogen, most people already have some level of antibodies against it from prior strep infections, and the body mounts a strong immune response after treatment.
How It Dissolves Blood Clots
Despite its name, streptokinase is not actually an enzyme. It cannot break down clots on its own. Instead, it works by hijacking a protein already circulating in your blood called plasminogen, which is your body’s built-in clot dissolver in its inactive form.
Normally, plasminogen gets activated when specific enzymes snip it at a precise location, triggering a shape change that turns it into plasmin, the active form that chews through the fibrin mesh holding clots together. Streptokinase skips the snipping entirely. It binds directly to plasminogen and forces it into an active shape without cutting it. Research has shown that the very first amino acid on the streptokinase protein is critical for this trick: when scientists mutated that single position, activity dropped by 10,000-fold or more, even though streptokinase could still latch onto plasminogen just fine. The binding happens first, then the shape change follows.
This mechanism has an important clinical consequence. Unlike some newer clot-dissolving drugs that primarily activate plasminogen at the clot surface, streptokinase activates plasminogen throughout the entire bloodstream. That creates a body-wide clot-dissolving state, which is effective but also raises the risk of bleeding elsewhere.
Conditions It Treats
Streptokinase is approved for several conditions where dangerous blood clots need to be dissolved quickly:
- Heart attack (acute myocardial infarction): The most common use. It’s given intravenously as soon as possible after symptoms begin to restore blood flow to the heart muscle.
- Pulmonary embolism: Large clots that travel to the lungs and block blood flow.
- Deep vein thrombosis: Clots in the deep veins of the legs that risk breaking loose and reaching the lungs.
- Arterial thrombosis: Clots blocking arteries in other parts of the body.
- Blocked catheters: It can clear clots that form inside tubes placed in blood vessels during medical treatment.
For heart attacks, timing matters enormously. In clinical studies, 1 million international units were infused intravenously over 30 to 60 minutes, ideally within four hours of symptom onset. The goal is to reopen the blocked coronary artery before too much heart muscle dies.
How It Compares to Newer Clot Busters
Streptokinase was the first widely available thrombolytic, but several newer drugs, particularly alteplase (a lab-made version of the body’s own clot-dissolving activator), have since entered the market. The key question has always been whether the newer, more expensive options save more lives.
The answer is nuanced. In two major international trials (GISSI-2 and ISIS-3), 30-day death rates were essentially identical: 8.9% with streptokinase versus 8.5% with alteplase in one trial, and 10.5% with streptokinase versus 10.3% with alteplase’s cousin duteplase in the other. However, the landmark GUSTO-I trial found that an accelerated alteplase regimen did produce a meaningful difference: 6.3% mortality compared to roughly 7.3% with streptokinase. That translates to about 10 extra lives saved per 1,000 patients treated.
Regardless of which drug is used, the single strongest predictor of survival is whether the blocked artery actually reopens. Patients with restored blood flow had a 4.0% mortality rate at 30 days, while those whose arteries stayed blocked faced 8.9%. Even the best thrombolytic regimens only achieve full reopening in about half of patients within 90 minutes.
In practice, streptokinase remains the preferred option in many healthcare systems because it costs a fraction of what alteplase does, and the mortality difference is relatively small. Where cost is not the primary concern, alteplase and its newer variants are generally favored.
How Long It Stays Active in the Body
Streptokinase has a biological half-life of about 80 to 85 minutes, meaning half the drug is cleared from the bloodstream in roughly an hour and a half. But its effects on the clotting system last considerably longer than the drug itself, because the plasmin it generates continues working after the streptokinase is gone.
An interesting quirk shows up during longer infusions. When streptokinase is given continuously over many hours (as sometimes done for deep vein thrombosis), drug levels in the blood actually decline progressively over the course of treatment, even while the infusion continues at the same rate. This likely reflects the body’s immune system ramping up antibody production that neutralizes the incoming drug, which reduces its effectiveness over time.
The One-Time-Only Problem
The most significant limitation of streptokinase is that it can generally only be used once in a person’s lifetime. Because it’s a bacterial protein, your immune system treats it as an invader. Antibodies against streptokinase begin forming within three to four days of treatment and peak about two weeks later. Those antibody levels then drop slowly but never fully return to baseline.
Studies have found that up to 51% of patients still carry enough antibodies to completely neutralize a standard dose of streptokinase four years after their initial treatment. Re-administration in someone with high antibody levels can mean the drug simply doesn’t work, and the risk of allergic reactions increases significantly. For this reason, anyone who has received streptokinase is advised never to receive it again. If they need thrombolytic therapy a second time, a different drug must be used.
Even people who have never received streptokinase may carry some baseline antibodies from prior strep infections, which can occasionally reduce the drug’s effectiveness on first use.
Bleeding Risk and Side Effects
The most serious risk of streptokinase is bleeding. Because it activates plasminogen throughout the bloodstream rather than just at the clot site, it creates a systemic state where your blood’s ability to form clots is temporarily impaired everywhere. Minor bleeding from puncture sites or the gums is common. More dangerous bleeding, including into the brain (hemorrhagic stroke), is rare but possible.
Allergic reactions are the other major concern, ranging from mild skin rashes and fever to rare cases of severe anaphylaxis. These reactions stem from the drug’s bacterial origin and are more likely in people with high pre-existing antibody levels. Low blood pressure during infusion is also relatively common and usually responds to slowing the infusion rate.
Streptokinase is not given to patients who have had recent surgery, active internal bleeding, a recent stroke, or severe uncontrolled high blood pressure, as the bleeding risk in these situations would outweigh the benefit of dissolving the clot.